GenVec Inc.
65 West Watkins Mill Road
Gaithersburg,
MD 20878
United States - Map
Phone: 240-632-0740
Fax: 240-632-0735
Web Site: http://www.genvec.com
| GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III trial for first-line treatment of inoperable, locally advanced pancreatic cancer. The company is also evaluating TNFerade biologic, wfor the treatment of various cancers, including esophageal cancer, rectal cancer, and head and neck cancer. In addition, it is developing TherAtoh, a preclinical program involving the delivery of the human atonal gene for the production of therapeutic proteins by cells in the inner ear. Further, GenVec uses its proprietary adenovector technology to develop vaccines for infectious diseases, including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus, and HSV-2. It has strategic alliances and research contracts with the U.S. department of homeland security, the U.S. department of agriculture, PATHÂ’S malaria vaccine initiative, the U.S. naval medical research center, and the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The company was founded in 1992 and is based in Gaithersburg, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Paul H. Fischer Ph.D., 59
Chief Exec. Officer, Pres |
$
410.00K |
$
98.00K | Mr. Douglas J. Swirsky CPA, CFA, 39
Chief Financial Officer, Principal Accounting Officer, Sr. VP, Corp. Sec. and Treasurer |
$
286.00K | N/A | Dr. Bryan T. Butman Ph.D., 56
Sr. VP of Vector Operations |
$
246.00K | N/A | Dr. Mark O. Thornton MD, MPH, PhD, 51
Sr. VP of Product Devel. |
$
304.00K | N/A | Dr. Milan Kovacevic M.D., Ph.D.,
Head of Clinical Operations |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.10% Nasdaq 
0.27%
Profile
